ATE522815T1 - Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1 - Google Patents

Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1

Info

Publication number
ATE522815T1
ATE522815T1 AT08156083T AT08156083T ATE522815T1 AT E522815 T1 ATE522815 T1 AT E522815T1 AT 08156083 T AT08156083 T AT 08156083T AT 08156083 T AT08156083 T AT 08156083T AT E522815 T1 ATE522815 T1 AT E522815T1
Authority
AT
Austria
Prior art keywords
methods
growth factor
placental growth
kidney failure
persons based
Prior art date
Application number
AT08156083T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Dietmar Zdunek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE522815T1 publication Critical patent/ATE522815T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
AT08156083T 2008-05-13 2008-05-13 Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1 ATE522815T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156083A EP2120051B1 (de) 2008-05-13 2008-05-13 Mittel und Verfahren zur Prognose von Nierenversagen bei Diabetikern auf Basis des plazentalen Wachstumsfaktors und löslichem Flt-1

Publications (1)

Publication Number Publication Date
ATE522815T1 true ATE522815T1 (de) 2011-09-15

Family

ID=39709041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08156083T ATE522815T1 (de) 2008-05-13 2008-05-13 Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1

Country Status (5)

Country Link
US (1) US8440463B2 (de)
EP (1) EP2120051B1 (de)
JP (1) JP2011520115A (de)
AT (1) ATE522815T1 (de)
WO (1) WO2009138364A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106361289A (zh) * 2016-09-30 2017-02-01 重庆工商大学 一种慢性肾衰竭预警系统
US11350887B2 (en) 2019-08-07 2022-06-07 Fresenius Medical Care Holdings, Inc. Systems and methods for detection of potential health issues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1615036B1 (de) 2004-07-07 2007-09-19 F.Hoffmann-La Roche Ag Kombination von Markern für Diabetes Typ 1 und 2
CA2511269A1 (en) * 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen

Also Published As

Publication number Publication date
US20110033942A1 (en) 2011-02-10
JP2011520115A (ja) 2011-07-14
US8440463B2 (en) 2013-05-14
EP2120051B1 (de) 2011-08-31
WO2009138364A2 (en) 2009-11-19
EP2120051A1 (de) 2009-11-18
WO2009138364A3 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
EP2215257A4 (de) Verfahren zur diagnose von tumorerkrankungen
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
JP2014526676A5 (de)
WO2011028912A3 (en) A biomarker for neurodegeneration in neurological disease
ATE537454T1 (de) Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
WO2009047283A3 (en) Means and methods for monitoring myocardial infarction and its treatment
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
ATE522815T1 (de) Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1
WO2011103330A3 (en) Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
BR112015014232A2 (pt) lesão renal aguda
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2006138292A3 (en) Ratiometric test strip and method
DE602006013109D1 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
WO2008103815A3 (en) Clinical intervention directed diagnostic methods
ATE546547T1 (de) Diagnose der chronischen abstossung
DE602007008370D1 (de) Verfahren zur Detektion der in-vivo-Aktivität von Neurotrypsin, Verwendung des Verfahrens und Verwendung des C-terminal 22-kDa-Fragments als Biomarker bei der Diagnose und Überwachung von Störungen im Zusammenhang mit Neurotrypsin
EP1993672A4 (de) Na/k-atpase-ligand
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2008024495A3 (en) Biomarkers associated with age-related macular degeneration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties